{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:24:55Z","timestamp":1790112295083,"version":"4.0.1"},"reference-count":71,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T00:00:00Z","timestamp":1644278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>With improved outcome following aggressive treatment in patients with grade 2 and 3 IDH-mutant (IDHmt), 1p\/19q codeleted oligodendroglioma and IDHmt, non-codeleted astrocytoma, prolonged surveillance is desirable for early detection of tumor growth and malignant transformation. Current National Comprehensive Cancer Network (NCCN) guidelines provide imaging follow-up recommendations based on molecular classification of lower-grade gliomas, although individualized imaging guidelines based on treatments received and after tumor recurrence are not clearly specified. Other available guidelines have yet to incorporate the molecular biomarkers that inform the WHO classification of gliomas, and in some cases do not adequately consider current knowledge on IDHmt glioma growth rate and recurrence patterns. Moreover, these guidelines also do not provide specific recommendations for concerning clinical symptoms or radiographic findings warranting imaging studies out of prespecified intervals. Focusing on molecularly defined grade 2 and 3 IDHmt astrocytomas and oligodendrogliomas, we review current knowledge of tumor growth rates and time to tumor progression for each tumor type and propose a range of recommended MRI surveillance intervals for both the newly diagnosed and recurrent tumor setting. Additionally, we summarize situations in which imaging is advisable outside of these intervals.<\/jats:p>","DOI":"10.1093\/neuonc\/noac031","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T20:12:37Z","timestamp":1643919157000},"page":"1035-1047","source":"Crossref","is-referenced-by-count":23,"title":["Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas"],"prefix":"10.1093","volume":"24","author":[{"given":"Jasmin","family":"Jo","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology and Oncology, East Carolina University , Greenville, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J","family":"van den Bent","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology\/Neurology, Erasmus MC Cancer Institute, Erasmus MC University Medical Center , Rotterdam , Netherland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burt","family":"Nabors","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Alabama at Birmingham , Birmingham, Alabama , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick Y","family":"Wen","sequence":"additional","affiliation":[{"name":"Center for Neuro-Oncology, Dana-Farber\/Brigham and Women\u2019s Cancer Center; Division of Neuro-Oncology, Department of Neurology, Brigham and Women\u2019s Hospital, and Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Schiff","sequence":"additional","affiliation":[{"name":"Department of Neurology, Division of Neuro-Oncology, University of Virginia , Charlottesville, Virginia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,2,8]]},"reference":[{"issue":"7","key":"2022070112584112600_CIT0001","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/neuonc\/noz033","article-title":"Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus","volume":"21","author":"Schiff","year":"2019","journal-title":"Neuro Oncol."},{"issue":"6","key":"2022070112584112600_CIT0002","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"issue":"8","key":"2022070112584112600_CIT0003","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"issue":"4","key":"2022070112584112600_CIT0004","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00401-015-1398-z","article-title":"IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas","volume":"129","author":"Olar","year":"2015","journal-title":"Acta Neuropathol."},{"issue":"4","key":"2022070112584112600_CIT0005","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bpa.12832","article-title":"cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading","volume":"30","author":"Louis","year":"2020","journal-title":"Brain Pathol."},{"issue":"5","key":"2022070112584112600_CIT0006","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00401-018-1913-0","article-title":"cIMPACT-NOW update 3: recommended diagnostic criteria for \u201cDiffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV\u201d","volume":"136","author":"Brat","year":"2018","journal-title":"Acta Neuropathol."},{"issue":"3","key":"2022070112584112600_CIT0007","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00401-020-02127-9","article-title":"cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas","volume":"139","author":"Brat","year":"2020","journal-title":"Acta Neuropathol."},{"issue":"18","key":"2022070112584112600_CIT0008","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1001\/jama.2012.12807","article-title":"Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas","volume":"308","author":"Jakola","year":"2012","journal-title":"JAMA."},{"key":"2022070112584112600_CIT0009","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3171\/2012.8.JNS12393","article-title":"Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and its impact on overall survival. A single-institution experience in 190 patients","volume":"117","author":"Ius","year":"2012","journal-title":"J Neurosurg."},{"issue":"8","key":"2022070112584112600_CIT0010","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1200\/JCO.2007.13.9337","article-title":"Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas","volume":"26","author":"Smith","year":"2008","journal-title":"J Clin Oncol."},{"issue":"3","key":"2022070112584112600_CIT0011","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat Rev Clin Oncol."},{"issue":"20160600","key":"2022070112584112600_CIT0012","article-title":"\u201cLow grade glioma\u201d: an update for radiologists","volume":"90","author":"Larsen","year":"2017","journal-title":"Br J Radiol."},{"issue":"5","key":"2022070112584112600_CIT0013","doi-asserted-by":"crossref","first-page":"e1002810","DOI":"10.1371\/journal.pmed.1002810","article-title":"Diagnosing growth in low-grade gliomas with and without longitudinal volume measurements: a retrospective observational study","volume":"16","author":"Fathallah-Shaykh","year":"2019","journal-title":"PLoS Med."},{"issue":"1","key":"2022070112584112600_CIT0014","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1023\/A:1011804404246","article-title":"The role of surveillance magnetic resonance imaging (MRI) scanning in detecting recurrent brain tumors in asymptomatic children","volume":"53","author":"Korones","year":"2001","journal-title":"J Neurooncol."},{"issue":"2","key":"2022070112584112600_CIT0015","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/mpo.1278","article-title":"Value of surveillance imaging in the management of medulloblastoma","volume":"38","author":"Yalcin","year":"2002","journal-title":"Med Pediatr Oncol."},{"issue":"2","key":"2022070112584112600_CIT0016","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3171\/2012.10.PEDS12307","article-title":"Recurrent pediatric central nervous system low-grade gliomas: the role of surveillance neuroimaging in asymptomatic children","volume":"11","author":"Udaka","year":"2013","journal-title":"J Neurosurg Pediatr."},{"key":"2022070112584112600_CIT0017","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3171\/jns.1996.84.5.0726","article-title":"Value of postoperative surveillance imaging in the management of children with some common brain tumors","volume":"84","author":"Steinbok","year":"1996","journal-title":"J Neurosurg."},{"key":"2022070112584112600_CIT0018","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s11060-018-2901-x","article-title":"The utility of routine surveillance screening with magnetic resonance imaging (MRI) to detect tumor recurrence in children with low-grade central nervous system (CNS) tumours: a systematic review","volume":"139","author":"Stevens","year":"2018","journal-title":"J Neurooncol."},{"issue":"5e","key":"2022070112584112600_CIT0019","first-page":"e410","article-title":"Does surveillance-detected disease progression yield superior patient outcomes in high-grade gliomas?","volume":"13","author":"Monroe","year":"2019","journal-title":"World Neurosurgery."},{"issue":"12","key":"2022070112584112600_CIT0020","first-page":"CD013137","article-title":"Interval brain imaging for adults with cerebral glioma","volume":"12","author":"Thompson","year":"2019","journal-title":"Cochrane Database Syst Rev."},{"key":"2022070112584112600_CIT0021"},{"key":"2022070112584112600_CIT0022"},{"issue":"14","key":"2022070112584112600_CIT0023","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1056\/NEJMoa1500925","article-title":"Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma","volume":"374","author":"Buckner","year":"2016","journal-title":"N Engl J Med."},{"issue":"11","key":"2022070112584112600_CIT0024","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/S1470-2045(16)30313-8","article-title":"Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study","volume":"17","author":"Baumert","year":"2016","journal-title":"Lancet Oncol."},{"issue":"18_suppl","key":"2022070112584112600_CIT0025","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1200\/jco.2006.24.18_suppl.1500","article-title":"Initial report of Radiation Therapy Oncology Group (RTOG) 9802: prospective studies in adult low-grade glioma (LGG)","volume":"24","author":"Shaw","year":"2006","journal-title":"J Clin Oncol."},{"issue":"29","key":"2022070112584112600_CIT0026","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1200\/JCO.19.02983","article-title":"Comprehensive Genomic Analysis in NRG Oncology\/RTOG 9802: a Phase III trial of radiation versus radiation plus procarbazine, lomustine (CCNU), and vincristine in high-risk low-grade glioma","volume":"38","author":"Bell","year":"2020","journal-title":"J Clin Oncol."},{"issue":"2","key":"2022070112584112600_CIT0027","doi-asserted-by":"crossref","first-page":"356","DOI":"10.4103\/ajns.AJNS_24_18","article-title":"Diffuse low-grade glioma\u2014changing concepts in diagnosis and management: a review","volume":"14","author":"Jooma","year":"2019","journal-title":"Asian J Neurosurg."},{"issue":"12","key":"2022070112584112600_CIT0028","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1007\/s00701-013-1886-7","article-title":"The silent phase of diffuse low-grade gliomas. Is it when we missed the actions?","volume":"155","author":"Pallud","year":"2013","journal-title":"Acta Neurochir (Wien)."},{"key":"2022070112584112600_CIT0029","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/ana.10528","article-title":"Continuous growth of mean tumor diameter in a subset of grade II gliomas","volume":"53","author":"Mandonnet","year":"2003","journal-title":"Ann Neurol."},{"issue":"3","key":"2022070112584112600_CIT0030","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/ana.20946","article-title":"Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas","volume":"60","author":"Pallud","year":"2006","journal-title":"Ann Neurol."},{"issue":"5","key":"2022070112584112600_CIT0031","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/neuonc\/nos331","article-title":"Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas","volume":"15","author":"Pallud","year":"2013","journal-title":"Neuro Oncol."},{"key":"2022070112584112600_CIT0032","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11060-009-9991-4","article-title":"Predictive value of multimodality MRI using conventional, perfusion, and spectroscopy MR in anaplastic transformation of low-grade oligodendrogliomas","volume":"97","author":"Hlaihel","year":"2010","journal-title":"J Neurooncol."},{"issue":"10","key":"2022070112584112600_CIT0033","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/neuonc\/noq055","article-title":"Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas","volume":"12","author":"Peyre","year":"2010","journal-title":"Neuro Oncol."},{"key":"2022070112584112600_CIT0034","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1002\/psp4.54","article-title":"Prediction of response to temozolomide in low-grade glioma patients based on tumor size dynamics and genetic characteristics","volume":"4","author":"Mazzocco","year":"2015","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"issue":"4","key":"2022070112584112600_CIT0035","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/neuonc\/nos069","article-title":"Dynamic imaging response following radiation therapy predicts long-term outcomes for diffuse low-grade gliomas","volume":"14","author":"Pallud","year":"2012","journal-title":"Neuro Oncol."},{"issue":"2","key":"2022070112584112600_CIT0036","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s11060-014-1641-9","article-title":"Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics","volume":"121","author":"Taal","year":"2015","journal-title":"J Neurooncol."},{"key":"2022070112584112600_CIT0037","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10143-009-0229-x","article-title":"Inter- and intrapatients comparison of WHO grade II glioma kinetics before and after surgical resection","volume":"33","author":"Mandonnet","year":"2010","journal-title":"Neurosurg Rev."},{"issue":"1","key":"2022070112584112600_CIT0038","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejrad.2008.06.013","article-title":"Volumes and growth rates of untreated adult low-grade gliomas indicate risk of early malignant transformation","volume":"72","author":"Rees","year":"2009","journal-title":"Eur J Radiol."},{"issue":"2","key":"2022070112584112600_CIT0039","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1148\/radiol.2532081623","article-title":"Low-grade gliomas: six-month tumor growth predicts patient outcome better than admission tumor volume, relative cerebral blood volume, and apparent diffusion coefficient","volume":"253","author":"Brasil Caseiras","year":"2009","journal-title":"Radiology."},{"issue":"4","key":"2022070112584112600_CIT0040","doi-asserted-by":"crossref","first-page":"247","DOI":"10.2217\/cns.15.16","article-title":"Radial expansion rates and tumor growth kinetics predict malignant transformation in contrast-enhancing low-grade diffuse astrocytoma","volume":"4","author":"Hathout","year":"2015","journal-title":"CNS Oncol."},{"issue":"noaa105","key":"2022070112584112600_CIT0041","first-page":"1522","article-title":"Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment","author":"Huang","year":"2020","journal-title":"Neuro Oncol."},{"issue":"5","key":"2022070112584112600_CIT0042","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/ana.21125","article-title":"Dynamic history of low-grade gliomas before and after temozolomide treatment","volume":"61","author":"Ricard","year":"2007","journal-title":"Ann Neurol."},{"key":"2022070112584112600_CIT0043","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11060-012-0831-6","article-title":"1p19q loss but not IDH1 mutations influences WHO grade II gliomas spontaneous growth","volume":"108","author":"Goze","year":"2012","journal-title":"J Neurooncol."},{"issue":"1","key":"2022070112584112600_CIT0044","doi-asserted-by":"crossref","first-page":"8522","DOI":"10.1038\/s41598-021-88023-y","article-title":"A survival analysis of surgically treated incidental low-grade glioma patients","volume":"11","author":"Zeng","year":"2021","journal-title":"Sci Rep."},{"issue":"5","key":"2022070112584112600_CIT0045","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3171\/JNS\/2008\/109\/11\/0835","article-title":"Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial","volume":"109","author":"Shaw","year":"2008","journal-title":"J Neurosurg."},{"issue":"4","key":"2022070112584112600_CIT0046","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ijrobp.2020.03.027","article-title":"Phase 2 Study of a Temozolomide-based chemoradiation therapy regimen for high-risk, low-grade gliomas: long-term results of radiation therapy oncology group 0424","volume":"107","author":"Fisher","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"3","key":"2022070112584112600_CIT0047","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1200\/JCO.2012.43.2674","article-title":"Phase III trial of chemoradiotherapy for anaplastic oligondendroglioma: long-term results of RTOG 9402","volume":"31","author":"Cairncross","year":"2013","journal-title":"J Clin Oncol."},{"issue":"6","key":"2022070112584112600_CIT0048","doi-asserted-by":"crossref","first-page":"vi15","DOI":"10.1093\/neuonc\/noz175.056","article-title":"ACTR-13. Final results with chemoradiotherapy for anaplastic oligodendroglial tumors from NRG oncology\/RTOG 9402","volume":"21","author":"Lassman","year":"2019","journal-title":"Neuro-Oncology."},{"issue":"3","key":"2022070112584112600_CIT0049","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1200\/JCO.2012.43.2229","article-title":"Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951","volume":"31","author":"van den Bent","year":"2013","journal-title":"J Clin Oncol."},{"issue":"Suppl_6","key":"2022070112584112600_CIT0050","doi-asserted-by":"crossref","first-page":"vi285","DOI":"10.1093\/neuonc\/noz219.1201","article-title":"LTBK-12. EORTC 26951, randomized study of adjuvant PCV after 59.4 Gr radiotherapy: very long term follo-up","volume":"21","author":"van den Bent","year":"2019","journal-title":"Neuro-Oncology."},{"issue":"6","key":"2022070112584112600_CIT0051","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/neuonc\/nor040","article-title":"International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors","volume":"13","author":"Lassman","year":"2011","journal-title":"Neuro Oncol."},{"issue":"11","key":"2022070112584112600_CIT0052","first-page":"1529","article-title":"Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide","volume":"18","author":"Wick","year":"2016","journal-title":"Neuro Oncol."},{"issue":"6","key":"2022070112584112600_CIT0053","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1470-2045(21)00090-5","article-title":"Adjuvant and concurrent temozolomide for 1p\/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study","volume":"22","author":"van den Bent","year":"2021","journal-title":"Lancet Oncol."},{"issue":"3","key":"2022070112584112600_CIT0054","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/neuonc\/nov182","article-title":"Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial","volume":"18","author":"Dubbink","year":"2016","journal-title":"Neuro-Oncology."},{"key":"2022070112584112600_CIT0055","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1200\/JCO.2013.49.3726","article-title":"Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH","volume":"32","author":"Cairncross","year":"2014","journal-title":"J Clin Oncol."},{"issue":"5","key":"2022070112584112600_CIT0056","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/neuonc\/noaa250","article-title":"Radiological assessment schedule for high-grade glioma patients during surveillance period using parametric modeling","volume":"23","author":"Ji","year":"2021","journal-title":"Neuro Oncol."},{"issue":"5","key":"2022070112584112600_CIT0057","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/neuonc\/noab053","article-title":"Is there an optimal MRI surveillance schedule for patients with high-grade glioma after standard-of-care therapy?","volume":"23","author":"Lim-Fat","year":"2021","journal-title":"Neuro Oncol."},{"issue":"5","key":"2022070112584112600_CIT0058","first-page":"719","article-title":"Incidence of pseudoprogression in low-grade gliomas treated with radiotherapy","volume":"19","author":"van West","year":"2017","journal-title":"Neuro Oncol."},{"issue":"5","key":"2022070112584112600_CIT0059","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/neuonc\/noz016","article-title":"Accelerated progression of IDH mutant glioma after first recurrence","volume":"21","author":"Miller","year":"2019","journal-title":"Neuro Oncol."},{"key":"2022070112584112600_CIT0060","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00066-019-01467-0","article-title":"Pattern of failure in anaplastic glioma patient with IDH1\/2 mutation","volume":"196","author":"Back","year":"2020","journal-title":"Strahlenther Onkol."},{"key":"2022070112584112600_CIT0061","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/S1470-2045(18)30362-0","article-title":"Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p\/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial","volume":"19","author":"van den Bent","year":"2018","journal-title":"Lancet Oncol."},{"issue":"6","key":"2022070112584112600_CIT0062","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1470-2045(11)70057-2","article-title":"Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas","volume":"12","author":"van den Bent","year":"2011","journal-title":"Lancet Oncol."},{"issue":"2","key":"2022070112584112600_CIT0063","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s13311-016-0507-6","article-title":"Modified criteria for radiographic response assessment in glioblastoma clinical trials","volume":"14","author":"Ellingson","year":"2017","journal-title":"Neurotherapeutics."},{"issue":"1","key":"2022070112584112600_CIT0064","doi-asserted-by":"crossref","first-page":"CNS28","DOI":"10.2217\/cns-2018-0007","article-title":"Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice","volume":"8","author":"Chukwueke","year":"2019","journal-title":"CNS Oncol."},{"issue":"1","key":"2022070112584112600_CIT0065","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3174\/ajnr.A6358","article-title":"Response assessment in neuro-oncology criteria for gliomas: practical approach using conventional and advanced techniques","volume":"41","author":"Leao","year":"2019","journal-title":"AJNR Am J Neuroradiol."},{"issue":"10","key":"2022070112584112600_CIT0066","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.3390\/cancers12103008","article-title":"Clinical management of diffuse low-grade gliomas","volume":"12","author":"Lombardi","year":"2020","journal-title":"Cancers (Basel)."},{"issue":"1","key":"2022070112584112600_CIT0067","first-page":"40","article-title":"Predictors of early, recurrent, and intractable seizures in low-grade glioma","volume":"8","author":"Jo","year":"2021","journal-title":"Neurooncol Pract."},{"issue":"2","key":"2022070112584112600_CIT0068","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/neuonc\/nor205","article-title":"Seizure characteristics and outcomes in 508 Chinese adult patients undergoing primary resection of low-grade gliomas: a clinicopathological study","volume":"14","author":"You","year":"2012","journal-title":"Neuro Oncol."},{"key":"2022070112584112600_CIT0069","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.clineuro.2018.10.001","article-title":"Diffuse low grade glioma after the 2016 WHO update, seizure characteristics, imaging correlates and outcomes","volume":"175","author":"Roberts","year":"2018","journal-title":"Clin Neurol Neurosurg."},{"issue":"1","key":"2022070112584112600_CIT0070","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.nec.2018.09.001","article-title":"Diffuse low-grade glioma-related epilepsy","volume":"30","author":"Pallud","year":"2019","journal-title":"Neurosurg Clin N Am."},{"issue":"1","key":"2022070112584112600_CIT0071","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/neuonc\/now190","article-title":"Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials","volume":"19","author":"Avila","year":"2017","journal-title":"Neuro Oncol."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noac031\/43219859\/noac031.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/24\/7\/1035\/44371626\/noac031.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/24\/7\/1035\/44371626\/noac031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T12:59:41Z","timestamp":1656680381000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/24\/7\/1035\/6524653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,8]]},"references-count":71,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,2,8]]},"published-print":{"date-parts":[[2022,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noac031","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2022,2,8]]}}}